1096 related articles for article (PubMed ID: 25108889)
1. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.
Schröder FH; Hugosson J; Roobol MJ; Tammela TL; Zappa M; Nelen V; Kwiatkowski M; Lujan M; Määttänen L; Lilja H; Denis LJ; Recker F; Paez A; Bangma CH; Carlsson S; Puliti D; Villers A; Rebillard X; Hakama M; Stenman UH; Kujala P; Taari K; Aus G; Huber A; van der Kwast TH; van Schaik RH; de Koning HJ; Moss SM; Auvinen A;
Lancet; 2014 Dec; 384(9959):2027-35. PubMed ID: 25108889
[TBL] [Abstract][Full Text] [Related]
2. Screening for prostate cancer.
Ilic D; Neuberger MM; Djulbegovic M; Dahm P
Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD004720. PubMed ID: 23440794
[TBL] [Abstract][Full Text] [Related]
3. Contamination in control group led to no effect of PSA-based screening on prostate cancer mortality at 9 years follow-up: Results of the French section of European Randomized Study of Screening for Prostate Cancer (ERSPC).
Villers A; Bessaoud F; Trétarre B; Grosclaude P; Malavaud B; Rebillard X; Iborra F; Daubisse L; Malavaud S; Roobol M; Heijnsdijk EA; de Koning HJ; Hugosson J; Rischmann P; Soulié M
Prog Urol; 2020 Apr; 30(5):252-260. PubMed ID: 32197936
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC).
Roobol MJ; Kerkhof M; Schröder FH; Cuzick J; Sasieni P; Hakama M; Stenman UH; Ciatto S; Nelen V; Kwiatkowski M; Lujan M; Lilja H; Zappa M; Denis L; Recker F; Berenguer A; Ruutu M; Kujala P; Bangma CH; Aus G; Tammela TL; Villers A; Rebillard X; Moss SM; de Koning HJ; Hugosson J; Auvinen A
Eur Urol; 2009 Oct; 56(4):584-91. PubMed ID: 19660851
[TBL] [Abstract][Full Text] [Related]
5. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
Jegu J; Tretarre B; Grosclaude P; Rebillard X; Bataille V; Malavaud B; Iborra F; Salama G; Rischmann P; Villers A
Prog Urol; 2009 Jul; 19(7):487-98. PubMed ID: 19559380
[TBL] [Abstract][Full Text] [Related]
6. Prostate-cancer mortality at 11 years of follow-up.
Schröder FH; Hugosson J; Roobol MJ; Tammela TL; Ciatto S; Nelen V; Kwiatkowski M; Lujan M; Lilja H; Zappa M; Denis LJ; Recker F; Páez A; Määttänen L; Bangma CH; Aus G; Carlsson S; Villers A; Rebillard X; van der Kwast T; Kujala PM; Blijenberg BG; Stenman UH; Huber A; Taari K; Hakama M; Moss SM; de Koning HJ; Auvinen A;
N Engl J Med; 2012 Mar; 366(11):981-90. PubMed ID: 22417251
[TBL] [Abstract][Full Text] [Related]
7. Screening and prostate-cancer mortality in a randomized European study.
Schröder FH; Hugosson J; Roobol MJ; Tammela TL; Ciatto S; Nelen V; Kwiatkowski M; Lujan M; Lilja H; Zappa M; Denis LJ; Recker F; Berenguer A; Määttänen L; Bangma CH; Aus G; Villers A; Rebillard X; van der Kwast T; Blijenberg BG; Moss SM; de Koning HJ; Auvinen A;
N Engl J Med; 2009 Mar; 360(13):1320-8. PubMed ID: 19297566
[TBL] [Abstract][Full Text] [Related]
8. A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer.
Hugosson J; Roobol MJ; Månsson M; Tammela TLJ; Zappa M; Nelen V; Kwiatkowski M; Lujan M; Carlsson SV; Talala KM; Lilja H; Denis LJ; Recker F; Paez A; Puliti D; Villers A; Rebillard X; Kilpeläinen TP; Stenman UH; Godtman RA; Stinesen Kollberg K; Moss SM; Kujala P; Taari K; Huber A; van der Kwast T; Heijnsdijk EA; Bangma C; De Koning HJ; Schröder FH; Auvinen A;
Eur Urol; 2019 Jul; 76(1):43-51. PubMed ID: 30824296
[TBL] [Abstract][Full Text] [Related]
9. Design-corrected variation by centre in mortality reduction in the ERSPC randomised prostate cancer screening trial.
Hakama M; Moss SM; Stenman UH; Roobol MJ; Zappa M; Carlsson S; Randazzo M; Nelen V; Hugosson J
J Med Screen; 2017 Jun; 24(2):98-103. PubMed ID: 27510947
[TBL] [Abstract][Full Text] [Related]
10. Results of the spanish section of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Update after 21 years of follow-up.
Luján Galán M; Páez Borda Á; Llanes González L; Romero Cajigal I; Berenguer Sánchez A
Actas Urol Esp (Engl Ed); 2020; 44(6):430-436. PubMed ID: 32147352
[TBL] [Abstract][Full Text] [Related]
11. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial.
Hugosson J; Carlsson S; Aus G; Bergdahl S; Khatami A; Lodding P; Pihl CG; Stranne J; Holmberg E; Lilja H
Lancet Oncol; 2010 Aug; 11(8):725-32. PubMed ID: 20598634
[TBL] [Abstract][Full Text] [Related]
12. A Detailed Evaluation of the Effect of Prostate-specific Antigen-based Screening on Morbidity and Mortality of Prostate Cancer: 21-year Follow-up Results of the Rotterdam Section of the European Randomised Study of Screening for Prostate Cancer.
de Vos II; Meertens A; Hogenhout R; Remmers S; Roobol MJ;
Eur Urol; 2023 Oct; 84(4):426-434. PubMed ID: 37029074
[TBL] [Abstract][Full Text] [Related]
13. Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC).
Schröder FH; Hugosson J; Carlsson S; Tammela T; Määttänen L; Auvinen A; Kwiatkowski M; Recker F; Roobol MJ
Eur Urol; 2012 Nov; 62(5):745-52. PubMed ID: 22704366
[TBL] [Abstract][Full Text] [Related]
14. Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence.
Hayes JH; Barry MJ
JAMA; 2014 Mar; 311(11):1143-9. PubMed ID: 24643604
[TBL] [Abstract][Full Text] [Related]
15. Absolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer Screening.
Auvinen A; Moss SM; Tammela TL; Taari K; Roobol MJ; Schröder FH; Bangma CH; Carlsson S; Aus G; Zappa M; Puliti D; Denis LJ; Nelen V; Kwiatkowski M; Randazzo M; Paez A; Lujan M; Hugosson J
Clin Cancer Res; 2016 Jan; 22(1):243-9. PubMed ID: 26289069
[TBL] [Abstract][Full Text] [Related]
16. Screening for prostate cancer (PC)--an update on recent findings of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
Schröder FH
Urol Oncol; 2008; 26(5):533-41. PubMed ID: 18774469
[TBL] [Abstract][Full Text] [Related]
17. Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial.
Martin RM; Donovan JL; Turner EL; Metcalfe C; Young GJ; Walsh EI; Lane JA; Noble S; Oliver SE; Evans S; Sterne JAC; Holding P; Ben-Shlomo Y; Brindle P; Williams NJ; Hill EM; Ng SY; Toole J; Tazewell MK; Hughes LJ; Davies CF; Thorn JC; Down E; Davey Smith G; Neal DE; Hamdy FC;
JAMA; 2018 Mar; 319(9):883-895. PubMed ID: 29509864
[TBL] [Abstract][Full Text] [Related]
18. Could Differences in Treatment Between Trial Arms Explain the Reduction in Prostate Cancer Mortality in the European Randomized Study of Screening for Prostate Cancer?
Carlsson SV; Månsson M; Moss S; Kwiatkowski M; Recker F; Tammela TLJ; Bangma C; Roobol MJ; Auvinen A; Hugosson J
Eur Urol; 2019 Jun; 75(6):1015-1022. PubMed ID: 30928162
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer mortality in the Finnish randomized screening trial.
Kilpeläinen TP; Tammela TL; Malila N; Hakama M; Santti H; Määttänen L; Stenman UH; Kujala P; Auvinen A
J Natl Cancer Inst; 2013 May; 105(10):719-25. PubMed ID: 23479454
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
